Mahamaya Lifesciences approved the notice for its 24th Annual General Meeting (AGM) and significant leadership restructuring during its board meeting on August 25, 2026. The company scheduled the AGM for September 29, 2026, to be held via video conference or other audio-visual means.

The Board also approved the appointment of new auditors for FY27. M/s HPN & Associates was appointed as Secretarial Auditor, M/s Chandramouli and Associates LLP as Internal Auditor, and M/s Yogesh Gupta and Associates as Cost Auditor. These appointments were effective from August 25, 2026, based on Audit Committee recommendations.

Leadership Restructuring

The Nomination and Remuneration Committee recommended several key changes to the board and management structure, effective from November 1, 2026, subject to shareholder approval.

Mr. Prashant Krishnamurthy will be redesignated from Executive Director to Managing Director. He simultaneously resigned from his role as Chief Financial Officer (CFO), effective October 31, 2026. Mr. Amarendra Mohapatra was appointed as the new CFO and Key Managerial Personnel (KMP).

Mr. Krishnamurthy Ganesan will step down as Managing Director to assume the role of Chairman and Executive Non-Independent Director. This transition marks a shift in executive responsibilities within the family-led management structure.

Board Appointments

The board appointed Mr. Bhagirath Choudhary as an Additional Independent Director for a three-year term starting August 25, 2026. Dr. Gopal Krishna Raju and Dr. Charudatta Digambar Mayee were reappointed as Independent Directors for their second three-year terms, effective December 11, 2026.

Mr. Kush Mishra was appointed as Company Secretary and Compliance Officer, effective August 25, 2026. He serves as both a Key Managerial Personnel under the Companies Act, 2013, and a Senior Management Personnel under SEBI LODR Regulations.

Remuneration Changes

The board approved revisions in remuneration for Mr. Krishnamurthy Ganesan, Mr. Prashant Krishnamurthy, and Mrs. Lalitha Krishnamurthy. These changes are effective from November 1, 2026, pending shareholder approval at the upcoming AGM.

Mahamaya Lifesciences Limited has uploaded its investor presentation to its corporate website, providing stakeholders with detailed insights ahead of the scheduled virtual investor and analyst meeting on August 07, 2026. The company disclosed the availability of the presentation on August 07, 2026, in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This proactive disclosure aims to equip investors with comprehensive information regarding the company’s operations, strategy, and financial performance before the interactive session.

The virtual meeting is scheduled to commence at 4:00 PM IST on Friday, August 07, 2026. Mahamaya Lifesciences explicitly stated that the presentation and the subsequent discussion will not contain any unpublished price-sensitive information (UPSI). All interactions will be based strictly on publicly available data, ensuring adherence to regulatory standards for fair disclosure. The meeting will be conducted via video conferencing as a group session, allowing broad participation from investors and analysts.

Meeting Details

Management Speakers

Senior leadership from Mahamaya Lifesciences will lead the discussion:

• Krishnamurthy Ganesan, Managing Director
• Prashant Krishnamurthy, Executive Director & CFO

Investors and analysts can register for the meeting through the provided QR code or via the Orim Connect platform. The company noted that the meeting may be cancelled, rescheduled, or postponed due to exigencies involving the analysts, investors, or company management.

Regulatory Compliance

Pursuant to Regulation 46(2) of the Listing Regulations, the intimation regarding the investor meet and the associated presentation has been uploaded to the company’s website at www.mahamayalifesciences.com . The disclosure was submitted to the Listing Compliance Department of BSE Limited, where the company is listed under Scrip Code 544611 on the BSE SME platform. The presentation serves as a supplementary document to the earlier schedule announcement made on August 04, 2026.

What This Means for Investors

The release of the investor presentation allows stakeholders to review the company’s strategic direction and operational metrics in detail before engaging with management. By restricting discussions to public data, Mahamaya Lifesciences maintains transparency while adhering to SEBI guidelines. Participants should prepare questions focused on publicly reported financials and operational updates.